Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179019 · ClinicalTrials.gov registry record · Phase 2
Calcium Channel Blockade in Primary Aldosteronism
A Phase 2 study of Primary Aldosteronism and Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral), sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04179019: Completed Phase 2 study of Primary Aldosteronism and Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral), sponsored by Brigham and Women's Hospital.
NCT04179019 is a Phase 2 study of Primary Aldosteronism and Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral) that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 15 participants, below the 3,268-participant average among 4 other Primary Aldosteronism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04179019, a Phase 2 study of Primary Aldosteronism and Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral), has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.
Primary Outcome
Change in 24h urinary aldosterone excretion rate in response to maximal amlodipine therapy
Conditions Studied
Interventions
- DRUG Amlodipine
Study Locations (1)
Massachusetts
- Anand Vaidya - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2023-12-30 |
| Phase | Phase 2 |
What the finished NCT04179019 record still lists
NCT04179019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 3,268-participant average among 4 other Primary Aldosteronism trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Primary Aldosteronism appearing as the primary indexed condition, and to 1 intervention - of which Amlodipine is the first listed.
NCT04179019 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04179019 about?
NCT04179019 is a clinical study titled "Calcium Channel Blockade in Primary Aldosteronism". This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.
What is the current status of trial NCT04179019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-09-01. Estimated completion is 2023-12-30.
What conditions does trial NCT04179019 study?
This clinical trial studies the following conditions: Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral).
What interventions are being tested in trial NCT04179019?
The interventions under investigation include: Amlodipine (DRUG).
Who is sponsoring clinical trial NCT04179019?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04179019 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Aldosteronism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CIN-107 in Adults With Primary Aldosteronism
COMPLETED · Phase 2
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
ACTIVE NOT RECRUITING · NA
-
Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI